Cancer - Statistics & Facts
Statistics and facts about cancer in the U.S. and worldwide
Cancer is the second leading cause of death in the United States, making it one of modern medicine’s greatest challenges. The percentage of the U.S. population who has or ever had cancer has increased over the past 14 years. Furthermore, men have a higher chance of developing cancer than women. For 2016, it was estimated there will be around 1.69 million new cases of cancer and some 596,000 deaths attributable to cancer in the United States.
Breast and the prostate are the most prevalent forms of cancer amongst women and men respectively. From an ethnic point of view, African-American men are the group with the highest incidence rate of cancer in the United States. Kentucky and Delaware are the U.S. states where the rate of cancer is the highest. New Mexico and Arizona on the other hand have the lowest number of new cancer cases per 100,000 inhabitants.
While incidence rates are increasing, cancer death rates have constantly fallen since 1990. Men have a higher risk of mortality from cancer than women. African-Americans are the ethnic group with the highest number of cancer-related deaths per 100,000 inhabitants. Lung and bronchial cancer cause the highest number of cancer-related deaths. Approximately 72,000 women and 86,000 men die from this type of cancer annually. The chance of surviving for a five-year period upon diagnosis has increased from 49 percent in the 1970s to 69 percent nowadays.
The cancer drug market is among the top pharmaceutical therapeutic areas both in the United States, and worldwide. Expenditure on oncologic medicine in the U.S. was worth some 39 billion U.S. dollars in 2015. The top cancer drug worldwide is Roche’s Rituxan, generating 7.1 billion U.S. dollars of revenue in 2015. The United States is a top global developer of new cancer drugs. As of autumn 2015, the number of cancer medicines in development was 836. Among them, the largest groups were aimed at treating solid tumors, lung cancer, and leukemia.
Picture: photodune.net / praisaeng
|Incidence & Death Rates||Values||Statistic|
|Incidence rate of cancer for women in the U.S. (per 100,000 population)||418.5||Details →|
|Incidence rate of cancer for men in the U.S. (per 100,000 population)||512.1||Details →|
|Deaths by cancer in the U.S. (per 100,000 population)||161.2||Details →|
|Cancer Drug Market||Values||Statistic|
|U.S. health spending on oncologics in the U.S.||$39.1bn||Details →|
|Global oncology revenue of Roche||$25,707m||Details →|
|Revenue of Revlimid (Celgene)||$5,801m||Details →|
- Percentage of population with cancer in the U.S. 2000-2014+Percentage of population with cancer in the U.S. 2000-2014
Percentage of U.S. population who has (or ever had) cancer between 2000 and 2014, by age
- Cancer - new cases worldwide 2012Cancer - new cases worldwide 2012
Percentage of cancer cases worldwide in 2012, by type of cancer
- Global oncology revenue by top ten pharmaceutical companies 2015 and 2022+Global oncology revenue by top ten pharmaceutical companies 2015 and 2022
Top 10 pharmaceutical companies based on global oncology revenue in 2015 and 2022 (in million U.S. dollars)*
- AstraZeneca's revenue from top product Crestor 2006-2016AstraZeneca's revenue from top product Crestor 2006-2016
- AstraZeneca's top products based on revenue 2010-2016AstraZeneca's top products based on revenue 2010-2016
- Biogen's top products based on revenue 2014-2016Biogen's top products based on revenue 2014-2016
- Roche Group's number of employees 2007-2016Roche Group's number of employees 2007-2016
- Global death rate - leading causes 2015Global death rate - leading causes 2015